A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Linzagolix (Primary) ; Estradiol/norethisterone
- Indications Endometriosis; Pelvic pain
- Focus Registrational; Therapeutic Use
- Acronyms EDELWEISS 2
- Sponsors ObsEva
- 11 Oct 2019 According to an ObsEva media release, data from this study will be presented at the 10th American Conference on Pharmacometrics (ACoP) meeting.
- 13 Jun 2019 Status changed from planning to recruiting.
- 09 May 2019 According to an ObsEva media release, the company expects to start enrolling patients in the second quarter of 2019.